Scientific American Highlights Study Supporting CardioDialysis Potential for Neuroinflammatory Diseases

Researchers at Trinity College Dublin have reported the first clinical evidence of blood-brain barrier disruption and associated inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy, according to Sigyn Therapeutics. The study, coinciding with a Scientific American article published on March 21, found that the blood-brain barrier may remain compromised and permeable for decades following an athlete's retirement from sports involving repetitive head trauma. When the integrity of the blood-brain barrier becomes compromised, inflammatory molecules and pathogenic toxins in the bloodstream are able to enter the brain, triggering neuroinflammation that can lead to abnormal accumulation of tau protein, a hallmark indicator of CTE.

The Trinity study adds to growing evidence indicating that systemic inflammation is a key driver of neuroinflammation associated with disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Scientific American published an article entitled "Brain's Protective Barrier Stays Leaky for Years after Playing Contact Sports" that discusses these findings in detail at https://www.scientificamerican.com/article/brains-protective-barrier-stays-leaky-for-years-after-playing-contact-sports/. Researchers observed that former athletes enrolled in the study appeared to exist in a persistent state of chronic hyperinflammation, highlighting the long-term consequences of repetitive head trauma.

Given its broad-spectrum mechanism, CardioDialysis is positioned as a potential adjunct therapy for neuroinflammatory conditions. Sigyn Therapeutics CEO Jim Joyce stated that CardioDialysis may play a meaningful role in slowing the progression of neuroinflammatory disorders, particularly in high-risk individuals or during early disease stages. The dual reduction of inflammatory and pathogenic factors from the bloodstream could help stabilize the blood-brain barrier, limiting the leakage of harmful molecules into the brain. This approach addresses the persistent inflammation observed in the Trinity College study, which documented barrier disruption lasting years after athletic careers ended.

Sigyn Therapeutics is pursuing a strategic transaction focused on using CardioDialysis to reduce systemic inflammation associated with traumatic brain injury, though the company's lead clinical indication remains cardiovascular disease treatment. The technology enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, potentially addressing the chronic hyperinflammation identified in the research. The Scientific American coverage brings attention to how blood purification technologies might intervene in neuroinflammatory processes by targeting systemic inflammation before it crosses into brain tissue through compromised barriers.

The implications extend beyond CTE to other neurological conditions where blood-brain barrier dysfunction contributes to disease progression. By reducing circulating inflammatory mediators, CardioDialysis could potentially slow neurodegenerative processes driven by systemic inflammation. The Trinity College findings provide clinical evidence supporting this therapeutic approach, demonstrating measurable barrier disruption in living patients rather than post-mortem examinations. This represents significant progress in understanding how repetitive head trauma leads to long-term neurological consequences and potential intervention points.